OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Deol on the Current Limitations of CAR T-cell Therapy in R/R Myeloma

March 22nd 2023

Abhinav Deol, MD, discusses the current limitations of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Bachanova on NK Cell Therapy in NHL

March 22nd 2023

Veronika Bachanova, MD, PhD, discusses findings from a spatial analysis of the tumor microenvironment in patients with non-Hodgkin lymphoma who received and responded to adoptive natural killer cell therapy.

Dr Stadler on Enhancing Diversity in Early Phase Clinical Trials For Underserved Communities

March 22nd 2023

Walter M. Stadler, MD, discusses his role within the Stand Up To Cancer® 4-team initiative, where he will aim to enhance diversity in early-phase clinical trials in underserved urban community.

Dr Domchek on the Importance of Germline Testing in Breast Cancer Care

March 22nd 2023

Susan Domchek, MD, FASCO, discusses the importance of germline testing in breast cancer care.

Dr Dreicer on the Potential Role of Triplet Therapy in De Novo Metastatic Prostate Cancer

March 22nd 2023

Robert Dreicer, MD, discusses the use of triplet therapy in the first-line management of de novo metastatic prostate cancer.

Dr Cummings on the Investigation of Osimertinib in EGFR-Mutant NSCLC

March 22nd 2023

Amy L. Cummings, MD, discusses the significance of the phase 3 FLAURA trial evaluating osimertinib in locally advanced or metastatic non–small cell lung cancer (NSCLC).

Dr. Godara on Approved CAR T-cell Therapies in Multiple Myeloma

March 21st 2023

Amandeep Godara, MBBS, discusses CAR T-cell therapies currently available for patients with multiple myeloma.

Dr. Wang on the Treatment Options for Unfit Patients With AML

March 21st 2023

Eunice Wang, MD, discusses treatment options in unfit patients with acute myeloid leukemia.

Dr. Chao on Key Trials Leading to FDA Approvals in Metastatic NSCLC

March 21st 2023

Yvonne Chao, MD, PhD, discusses key trials leading to FDA approvals in metastatic non–small cell lung cancer.

Dr. O'Regan on the RIGHT Choice Trial in HR+/HER2- Breast Cancer

March 21st 2023

Ruth M. O’Regan, MD, discusses how results from the phase 2 RIGHT Choice trial could influence the treatment paradigm in hormone receptor–positive, HER2-negative breast cancer.

Dr. Burns on the Evolving Use of ADCs in HER2-mutant NSCLC

March 21st 2023

Timothy Burns, MD, PhD, discusses the evolving use of antibody-drug conjugates in HER2-mutant non–small cell lung cancer.

Dr. Patel on the Background of the SWOG S1801 Trial in Melanoma

March 20th 2023

Sapna Patel, BA, MD, discusses the rationale for evaluating the use of pembrolizumab before and after surgery for patients with advanced melanoma.

Dr. Henick on Further Exploring the Immune Microenvironment in Lung Cancer

March 20th 2023

Brian Henick, MD, discusses the importance of further exploring biomarkers in the immune microenvironment for immunotherapy in patients with lung cancer.

Dr. Randall on the Diagnosis of Mesenchymal Chondrosarcoma

March 20th 2023

R. Lor Randall, MD, FACS, discusses, the importance of correctly diagnosing mesenchymal chondrosarcoma.

Dr. Garon on the Current Landscape of PD-L1 and CTLA-4 Inhibitor Regimens in NSCLC

March 20th 2023

Edward B. Garon, MD, MS, discusses the use of PD-L1 inhibitor and CTLA-4 inhibitor combinations in non–small cell lung cancer.

Dr. Brunner on the Use of CAR T-cell Therapy to Improve Post-ASCT Responses in Multiple Myeloma

March 20th 2023

Matthew Brunner, MD, discusses how the phase 2 BMT CTN 1902 trial of anti-BCMA CAR T-cell therapy will attempt to address an area of unmet need in multiple myeloma.

Drs Edelman and Fleisher on Personalizing and Adapting Treatment Approaches in Clinical Trials

March 17th 2023

Martin Edelman, MD, and Linda Fleisher, PhD, MPH, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

Drs Gerber and Nwachukwu on the Importance of Streamlining Clinical Research in Cancer Care

March 17th 2023

David Gerber, MD, and Chika Nwachukwu, MD, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

Drs El-Khoueiry and Hughes-Halbert on the Importance of a Multidisciplinary Approach in Cancer Care

March 17th 2023

Anthony B. El-Khoueiry, MD, and Chanita Hughes-Halbert, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

Dr. Mitzman on Neoadjuvant Nivolumab Plus Chemotherapy in NSCLC

March 17th 2023

Brian Mitzman, MD, FACS, FCCP, discusses findings from the phase 3 CheckMate 816 trial in patients with resectable non–small cell lung cancer.